Addiction Medicine in Primary Care

Devang Gandhi, MB, BS, MD, FRCPsych, DFASAM, DFAPA
Clinical Associate Professor
Director. Addiction Medicine/Psychiatry Fellowship Programs
University of Maryland School of Medicine
Objectives

• Upon completing this activity, participants will learn:
  1) The background on the establishment of addiction medicine as a subspecialty.
  2) How to identify and evaluate patients with opioid, alcohol and benzodiazepine use disorders.
  3) How to manage opioid and alcohol use disorders with medications.
Disclosures

Minor stock-holdings in pharmaceutical companies—none relevant to current presentation.
Outline

1. Addiction Medicine as a new subspecialty
2. Background
3. Primary Care involvement in managing substance use disorders.
   a. Why?
   b. How?
      a. Screening
      b. Assessment including interpretation of drug tests
      c. “Medication Assisted Treatment” for opioid and alcohol use disorders
Medicine Responds to Addiction

ADDICTION MEDICINE: THE NEWEST MEDICAL SUBSPECIALTY
ADM SLIDES COURTESY OF DR. KEVIN KUNZ, EXECUTIVE VP, THE ADDICTION MEDICINE FOUNDATION
Which Organizations Are Involved?

- American Board of Addiction Medicine (ABAM)
- The Addiction Medicine Foundation (TAMF)
- American Board of Medical Specialties (ABMS)
- American Board of Preventive Medicine (ABPM)
- ACGME
- National Center for Physician Training in Addiction Medicine (NCPTAM)
- Addiction Medicine Fellowship Directors Association (AMFDA)
Incorporated August, 2007

(Previously named The ABAM Foundation)
Operational Success, 2007-16

- 3,900 ABAM diplomates
- ABAM MOC: 85% enrollment
- 45+ fellowships designed, established, TAMF accredited
- Fellowship goal of 125 by 2025 on track
- $17 Million Invested
Strategic Success

– ABMS ADM recognition announced March 2016

– ACGME program accreditation process underway

– Linkages Built
  • House of Medicine, House of Addiction Medicine
  • Government
  • Philanthropy
  • Other sectors
Impact of ABMS Recognition of ADM on Medicine and Health Care

- Addresses stigma and ignorance by the medical profession
- Addiction is recognized as preventable and treatable
- Inclusion of ADM in GME and thus into medical education
- Improved quality and access to care
- True parity for patients and physicians
Benefit to Patients, Families, and Public Health

ADM: A Specialized Field of Medicine

Training-ACGME
- ABAMF Residencies
- Standards & Procedures
- Core Competencies

Certification-ABMS
- Maintenance of Certifications
- Exam
- Standards & Procedures
- Candidates & Diplomates

ABAM Foundation

ABAM
American Board of Medical Specialties
- Recognition of Addiction Medicine announced March 2016
  - Addiction Medicine is a multispecialty subspecialty

American Board of Preventive Medicine
- Administrative sponsoring board for Addiction Medicine
Background

HOW BIG IS THE PROBLEM? WHY SHOULD PHYSICIANS DEAL WITH IT?
Consider This

- A medical condition
  - runs a chronic course
  - causes many serious medical and surgical complications
  - is highly debilitating and potentially fatal
  - even when it does not kill, it has a profound impact on the health and lives of the patients, their families, and the society.
Now Consider This

• This condition has highly efficacious, cost-effective and safe treatments

• Treatment can lead to a full or partial remission in over 80% of cases and cut the risk of death by over 75%

• But less than a quarter of the patients can get it.

• What if we were talking about cancer, heart disease, diabetes, or virtually any other condition but an addiction?
Continuum of Substance Use

Percent of Population Age 12+
by Level of Substance Use*

<table>
<thead>
<tr>
<th>Category</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Never Used</td>
<td>12.7</td>
</tr>
<tr>
<td>No Current Use</td>
<td>25.2</td>
</tr>
<tr>
<td>Non-Risky Use</td>
<td>14.5</td>
</tr>
<tr>
<td>Risky Use</td>
<td>31.7</td>
</tr>
<tr>
<td>Addiction</td>
<td>15.9</td>
</tr>
</tbody>
</table>

“An Urgent Health Crisis...”*

• “The opioid epidemic” is a growing problem nationally, with opioid use, misuse, addiction, overdose, death.
• Ever larger numbers of patients needing and receiving treatment for opioid use disorder.
• Still, fewer than a quarter of the patients who need treatment actually receive it.
  – (*Vivek Murthy, MD, Former US Surgeon General)
More than 64,000 Americans died from drug overdoses in 2016 -- 64,070

Source: CDC WONDER
Current Epidemic of Opioid Addiction

• US consumes
  – >99% of the world’s hydrocodone,
  – >80% of oxycodone,
  – >65% of hydromorphone
  – >80% of all opioids prescribed in the world.

• US has <5% of the world’s population

• Primary Care providers account for about half of the opioid prescriptions

*Source: Medscapec
"We know of no other medication routinely used for a nonfatal condition that kills patients so frequently."

-Tom Frieden, MD
Former Director, CDC
Opioid Prescription Trends

High Dose =/>90 MME/day

Opioid Prescription Trends

Sources of Prescription Opioids Among Past-Year Non-Medical Users

- Given by a friend or relative for free
- Prescribed by ≥1 physicians
- Stolen from a friend or relative
- Bought from a friend or relative
- Bought from a drug dealer or other stranger
- Other

---

a Obtained from the US National Survey on Drug Use and Health, 2008 through 2011.5
b Estimate is statistically significantly different from that for highest-frequency users (200-365 days) (P< .05).
c Includes written fake prescriptions and those opioids stolen from a physician’s office, clinic, hospital, or pharmacy; purchases on the Internet; and obtained some other way.

Mea culpa

"What I was trying to do was create a narrative so that the primary care audience would ... feel more comfortable about opioids in a way they hadn't before. ... and because the primary goal was to destigmatize, we often left evidence behind......Clearly if I had an inkling of what I know now then, I wouldn't have spoken in the way that I spoke. It was clearly the wrong thing to do."

Russell Portenoy, MD

(Quoted on CNN.com: “Opioid history: From 'wonder drug' to abuse epidemic” by Sonia Moghe, 10/14/2016)
The “Evidence”

**Correspondence**

Addiction Rare in Patients Treated with Narcotics


<table>
<thead>
<tr>
<th>Article</th>
<th>Citing Articles (265)</th>
</tr>
</thead>
</table>

**To the Editor:**

Recently, we examined our current files to determine the incidence of narcotic addiction in 39,946 hospitalized medical patients\(^1\) who were monitored consecutively. Although there were 11,882 patients who received at least one narcotic preparation, there were only four cases of reasonably well documented addiction in patients who had no history of addiction. The addiction was considered major in only one instance. The drugs implicated were meperidine in two patients,\(^2\) Percodan in one, and hydromorphone in one. We conclude that despite widespread use of narcotic drugs in hospitals, the development of addiction is rare in medical patients with no history of addiction.

Jane Porter  
Hershel Jick, M.D.  
Boston Collaborative Drug Surveillance Program Boston University Medical Center, Waltham, MA 02154

**2 References**

   CrossRef | Web of Science | Medline

   CrossRef | Web of Science | Medline
Citations of the 1980 Letter

Leung et al., NEJM 2017
ADDICTION AS A DISEASE
Addiction, a Disease

- Known risk factors:
  - family history
  - male sex
  - genes play a central role
- Typical course and outcomes:
  - chronic
  - punctuated by periods of abstinence followed by relapse
  - sometimes fatal
- Current conceptualization focuses on compulsive use rather than dependence or withdrawal
  - addiction diminishes, but does not completely eliminate voluntary behavioral control
In humans, the capacity for cognitive control over reward-seeking is a relatively stable trait that predicts life success.

Deficits in cognitive control, such as in ADHD, are also known to increase vulnerability to substance use.

Drugs “hijack” the reward system by direct pharmacological action, so that drug-seeking acquires salience over all other goals.

Rational goals such as self-care, work, parenting, etc, are devalued.
## Success Rates in Drug Treatment

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Success* rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol dependence</td>
<td>50 (40-70)</td>
</tr>
<tr>
<td>Opioid dependence</td>
<td>60 (50-80)</td>
</tr>
<tr>
<td>Cocaine dependence</td>
<td>55 (50-60)</td>
</tr>
<tr>
<td>Nicotine dependence</td>
<td>30 (20-40)</td>
</tr>
</tbody>
</table>

* Defined as >50% reduction in drug use at 6 months

# Compliance and Relapse in Medical Disorders

<table>
<thead>
<tr>
<th></th>
<th>Compliance and relapse</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DM (insulin dependent)</strong></td>
<td></td>
</tr>
<tr>
<td>Medication regimen</td>
<td>&lt;50%</td>
</tr>
<tr>
<td>Diet and foot care</td>
<td>&lt;30%</td>
</tr>
<tr>
<td>Relapse*</td>
<td>30-50%</td>
</tr>
<tr>
<td><strong>Hypertension</strong></td>
<td></td>
</tr>
<tr>
<td>Medication regimen</td>
<td>&lt;30%</td>
</tr>
<tr>
<td>Diet</td>
<td>&lt;30%</td>
</tr>
<tr>
<td>Relapse*</td>
<td>50-60%</td>
</tr>
</tbody>
</table>

*Retreatment within 12 months by physician, emergency room or hospital.*

MANAGING PATIENTS IN PRIMARY CARE
SCREENING AND ASSESSMENT
Case Identification

• Self report
• Collateral information.
• Red flags- “lost” prescriptions; early refill requests.
• Health complications related to drug use
• PDMP database.
• A positive drug test.
• Maintain a non-judgmental, supportive, approach.
Screening Tool: CAGE-AID

• The CAGE-AID (“Adapted to Include Drugs”)* should be preceded by these two questions:

1. Do you drink alcohol?
2. Have you ever experimented with drugs?

CAGE-AID

In the last three months: (Yes/No responses)

1. Have you felt you should **Cut down** or stop drinking or using drugs? (You may ask more specifically about beer, wine, liquor, marijuana, non-prescribed medications, etc, based on clinical suspicion)

2. Has anyone **Annoyed** you or gotten on your nerves by telling you to cut down or stop drinking or using drugs?

3. Have you felt **Guilty** or bad about how much you drink or use drugs?

4. Have you been waking up wanting to have an alcoholic drink or use drugs (**Eye-opener**)?

A “Yes” response to one or more questions should lead to further exploration.
Single-question Screens

• “How many times in the past year have you used an illegal drug or used a prescription medication for nonmedical reasons?”
• “How many times in the past year have you had X or more drinks in a day?” (X = 5 for men, X = 4 for women).

Assessment

- If non-medical substance use is identified on screening follow up with questions about:
  - Which substance/s?
  - How much?
  - How often?
  - Route of administration?
  - When last used?
  - Past experience of withdrawal?
  - Use of any other drugs/alcohol?
  - Interest in seeking treatment?
Stage of Change

Pay attention to patient’s Stage of Readiness to Change:

- Precontemplation: “I don’t have a problem”
- Contemplation: “Maybe, I do have a problem”
- Preparation: “How can I get treatment?”
- Action: “I am already in treatment”
- Maintenance: “I am in treatment and haven’t used since_____”
- Relapse: “I was doing well, but fell off the wagon”
MAKING SENSE OF DRUG TESTS
“You’re fired, Jack. The lab results just came back, and you tested positive for Coke.”
Common Problems

• Very often, too much is read into single drug test results
• Complexity of drug testing is not often evident to people who use it
• Serious consequences may follow from misinterpretation of drug tests, e.g., termination from treatment, loss of a job, separation of a child from its parent, imprisonment, inappropriate medical treatment.
“Positive” and “Negative”

• The terms “Clean” and “Dirty” have pejorative connotations and should be avoided.
• What is meant by a “Positive” test?
• What is meant by a “Negative” test?
Definitions

– **Positive Test:** A positive test for a substance implies that the specimen contained the particular substance at a concentration exceeding a predetermined cut-off level.

– **Negative Test:** A negative test for a substance implies that the specimen did not contain the substance that was tested for, or contained the particular substance at a concentration below a predetermined cut-off level. Substances not tested for may be present.
Opioids

• Three classes of opioids
  – Natural (“Opiates”)-alkaloids from *Papaver somniferum* alkaloids in opium: morphine, codeine, thebaine
  – Semisynthetic: heroin, oxycodone, oxymorphone, hydrocodone, hydromorphone, buprenorphine
  – Synthetic: methadone, fentanyl, propoxyphene, meperidine
Testing for Opioids

- Two main testing techniques
  - Immunoassay for screening
  - Gas Chromatography-Mass Spectrometry for confirmation
- The common “Opiates” test on screening panels tests for morphine using immunoassay
- There is some cross-reactivity between certain semisynthetics and the opiates test, especially at high dose levels (e.g., 5% cross-reactivity for oxycodone)
- Others, including methadone and buprenorphine, have to be tested for individually
Opioid Metabolism

Not comprehensive pathways, but may explain presence of apparently unprescribed drugs.

Heroin → 6-MAM

C-6G → Codeine → Morphine → M-3G

Minor → Hydrocodone

Minor → Hydromorphone

→ Dihydrocodeine

→ Dihydromorphone

Testing for Opioids

- Heroin (di-acetylmorphine) is rapidly converted after ingestion to mono-acetylmorphine (within minutes)
- Mono-acetylmorphine also has a short half-life (about 8 hours) and is converted to morphine
- Detection time for heroin is extended indirectly by identifying “cutting agents” such as quinine
- A part of ingested codeine is converted to morphine
- A small proportion of oxycodone is converted to morphine
Alcohol Testing

- Can be tested for in blood, urine or breath, but short window of detection
- May be detected for a longer period by testing urine for ethyl glucuronide (EtG)
- Several other biomarkers may be helpful in detecting recent heavy drinking: AST, ALT, GGT, CDT, MCV, etc.
- May get a positive urine test for ethanol in some diabetic patients due to fermentation of sugar in urine
- False positives possible from non-beverage alcohols, e.g., isopropyl alcohol
Benzodiazepines

- Tests generally detect oxazepam/nordiazepam which are common metabolites of many benzodiazepines.
- Hard to identify which benzodiazepine was used based on the test
- Test may remain positive for weeks after ingestion of long-acting benzodiazepines with active metabolites (e.g., diazepam (Valium®) or chlordiazepoxide (Librium®)
- False positives reported with sertraline (Zoloft®) and oxaprozin.
Benzodiazepine Metabolism

CYP 3A4/2C19
Important to Remember

• A drug test does **NOT** diagnose
  • Substance use disorder
  • Physical dependence
  • Impairment
  • Diversion
• An unexpected result should lead to a differential diagnosis and a conversation rather than a jump to a definitive conclusion
MANAGEMENT
Opioid “Detoxification”

- Term “detox” commonly used but a misnomer.
- Alternative term “medically supervised withdrawal” favored by some.
- Does not produce any lasting benefit.
- >90% relapse quickly after a short detox.
- High risk of death from overdose after a detox due to loss of tolerance.
Recommend Maintenance

• All patients should be offered long-term maintenance treatment
• If the patient accepts, initiate a referral or start buprenorphine (or methadone, if inpatient) as soon as possible to ensure a seamless transition to treatment
• Continue buprenorphine until transfer and provide a hand-off to the program/prescriber
MEDICATION “ASSISTED” TREATMENT
Medication Assisted Therapy (MAT) for Opioids

- Opioid Full Agonist - Methadone
- Opioid Partial Agonist - Buprenorphine
- Opioid Antagonist -
  - Naltrexone
  - Extended Release Naltrexone Injection
Methadone

- Narcotics Addiction Treatment Act of 1974 limited treatment of opioid dependence with methadone primarily to regulated opiate agonist treatment programs
- Nationally this system can accommodate approximately 250,000 individuals with opioid use disorder
- Currently over 2 million individuals are estimated to be addicted to heroin and prescription opioids
Buprenorphine

- Schedule III medication, FDA approved for use with a waiver under Drug Addiction Treatment Act of 2000
- Can be used in an office based practice by qualified physicians with a DEA waiver ("X number")
- Prescribing recently extended to qualified NPs and PAs with additional training
- Most commonly prescribed as buprenorphine+ naloxone combination formulation (Suboxone film/Zubsolv tab/generic tabs) in a 4:1 ratio available in 2/4/8/12mg (or equivalent Zubsolv) strengths
Effectiveness

• Methadone has been in wide use since 1972 and buprenorphine since 2002
• Methadone and buprenorphine are among the most researched and effective medications in all of medicine
• Strong evidence that both are about equally effective in promoting abstinence from opioids and retaining people in treatment
• Both
  – Reduce opioid cravings
  – Reduce opioid use
  – Reduce criminal activity
  – Reduce complications of opioid use
  – Reduce mortality
Impact of Methadone Maintenance on Mortality

- Swedish 5-8 year follow-up study of Methadone Maintenance Treatment (MMT):
  - 115 “street” heroin users not on MMT vs 166 on MMT
    - Mortality in non-MMT group 63x expected rate for age and gender in the general population
    - Mortality in MMT group 8x
    - Mortality in 53 MMT pts involuntarily expelled from MMT 55x
    - Mortality in 34 “rehabilitated” patients therapeutically withdrawn from methadone 4x

(Gronbladh et al, Acta Psychiat Scand, 1990)
Methadone: Effectiveness

• Among the most effective medications in medicine:
  – Increases treatment retention- >= 70% at 90 days.
  – Patients maintained on >80mg/day have a much higher retention rate than those on <60mg/day (up to 5x in one study)
  – >70% reduction in injection drug use
  – Reduces HIV risk behavior/ seroconversion (7x reduction over 18 months in seroconversion vs not–in-treatment controls)
  – Reduces crime and recidivism
  – Reduces mortality (0.8% vs 8.3% in one study; 4x reduction across 5 studies)
Effect of Methadone Treatment on Crime Days

Mean Crime Days Per Year

237.5
220
200
180
160
140
120
100
80
60
40
20
0

23.5 Months Pretreatment
4-Month Admission Period
1
2
3
4
5
6+

Years In Methadone Maintenance Treatment

70.8% Decline In Crime Days
94%

(Ball and Ross, 1991)
Methadone Effect on HIV Seroconversion

Metzger et al., JAIDS, 1993; 6; 1049
Safety

• Low risk of morbidity and mortality when used under proper supervision
• Caution needed during induction period
• Few side effects - but may prolong QTc
• Elevated risk when methadone and buprenorphine are used with CNS depressants - especially benzodiazepines and alcohol
Cost and Ease of Delivery

– Cost-effective:
  • Annual cost of methadone maintenance is approximately $5000 per patient
  • Buprenorphine maintenance (approx $6-8000) and injectable naltrexone (approx $15000) cost more
  • But all cost far less than incarceration (approx $30000)

– Scalable:
  • Can be delivered relatively easily to large numbers of patients
  • Recent increase in buprenorphine cap helps
Buprenorphine Maintenance vs Withdrawal RCT: Retention

(Kakko et al., Lancet, 2003)
Buprenorphine in Primary Care: Barriers

- Waiver: Easy to get
- Induction: Can be done at home
- Counseling: Recommended but not required
  - “have capacity to refer”
- Drug testing: Can be done on site or via lab
- Concern about diversion: Not widespread
- Concern about patient population: Much easier to manage than an actively using patient
Role of Counseling

- Multicenter randomized clinical trial- n=653
- Patients randomized to standard medical management (SMM) or SMM plus counseling
- At 3 & 12 weeks of buprenorphine separate counseling did not change outcomes

Abuse/Diversion Risk

Cicero, NEJM 2005
Bottom-line

- Given their predictable effectiveness in reducing opioid use and preventing associated complications, MAT with methadone or buprenorphine should be considered first-line treatment and accessible to ALL patients with opioid use disorders.
Antagonist Maintenance

- Oral naltrexone was approved for opioid dependence in 1984
- Injectable extended-release naltrexone was approved for opioid dependence in 2010
- Advantages include
  - No physical dependence
  - No risk of diversion
  - Not a controlled medication
- But
  - Less strong evidence of effectiveness
  - Lower patient acceptability and adherence
  - Need for abstinence from opioids before induction
  - Possible greater risk of overdose after drop-out
  - High cost of injectable extended release naltrexone
Special Situations: Acute Pain Management

- Acute pain should be managed per normal practice while maintaining methadone at usual doses.
- Buprenorphine should be discontinued while acute pain management proceeds and then reinstated after stopping the pain medication, allowing sufficient time for it to clear the patient’s system.
- Naltrexone (oral) should be discontinued as with buprenorphine.
- Patients on injectable naltrexone may be more difficult to manage and a pain medicine consultation should be obtained.
Special Situations: Acute Pain Management

- Patients with opioid use disorders may need higher than normal doses of opioid pain medications due to tolerance.
- Pain medication prescriptions should be for short duration and closely monitored.
- Avoid benzodiazepines.
- Naloxone should be co-prescribed and patient and family trained in its use in an overdose situation for all patients on opioid pain medications.
Special Situations: Pregnancy

- Recommend methadone or buprenorphine maintenance as soon as pregnancy is confirmed. No evidence yet to support naltrexone for use in pregnant patients.
- Start MAT, if patient agrees and refer to a maintenance program
- MAT doses may need upward adjustment as pregnancy progresses and reduction after delivery
Overdose Education and Naloxone Distribution

• OEND programs now operate in many states
• Important element of any effort to reduce overdose deaths
• Educates people with opioid addiction, their family members, pain patients on opioids and general public about overdose and provides naloxone for use in an overdose emergency
• Shown to reduce overdose deaths
• Recommend co-prescribing naloxone to anyone receiving a prescription for opioids
MEDICATIONS FOR ALCOHOL USE DISORDER
What to Expect

- Medication for AUD can be a useful adjunct to psychosocial treatment
- The effect sizes for all available treatments for AUD are much smaller compared to opioid agonist treatments for opioid use disorder
- Incorporation of medication is increasingly considered the standard of care
- Patient acceptance tends to be relatively low, but growing
FDA Approved Medications: Disulfiram

• Antabuse®: The first one approved
• Sometimes called “aversive therapy”
• Causes an unpleasant reaction (“Disulfiram-Ethanol Reaction”) with alcohol
• Observed treatment works better as compliance is a common problem
• Works well in carefully selected patients: motivated, not impulsive/risk-taker, good support system
• Can cause liver dysfunction and some unpleasant side effects
How Does It Work?

Kalra et al, OpenJPsych, 2014
Disulfiram-Ethanol Reaction

- Occurs due to the build-up of acetaldehyde
- Signs/symptoms include: Flushing, nausea, vomiting, sweating, drop in blood pressure (sometimes severe), irregular heart rhythm (potentially dangerous; rarely, fatal)
- Severity of reaction varies- some people may have it even with small amounts of alcohol (e.g., in food/medication/mouthwash)
- Reaction may occur up to 7-14 days after stopping disulfiram
FDA Approved Medications: Naltrexone

- **Revia®**: Mu opioid receptor antagonist
- Reduces cravings and makes alcohol less reinforcing
- Generally well-tolerated, once daily pill
- May also cause liver dysfunction
- Compliance can be a problem
- Long-acting injectable formulation- Vivitrol®- can improve adherence
- There may be a genetic basis to response to naltrexone
FDA Approved Medications: Acamprosate

• Campral®: Glutamate receptor modulator, may work by dampening the glutamate surge that follows cessation of drinking
• Also reduces cravings and makes alcohol less reinforcing
• Generally well-tolerated, no effect on the liver, but needs to be taken three times daily, so compliance can be a problem
• Some studies show it to be no better than placebo—also based in genetics
While disulfiram requires total abstinence, the primary objective of treatment with other medications is to reduce drinking and, therefore, reduce harm.

Some medications are also being promoted as targeted therapy, e.g., nalmefene (available in Europe), for use prior to exposure to drinking situations.
BENZODIAZEPINES
AND THE “Z” DRUGS
Black Box Warning

• “Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.”
Most Prescribed Psychiatric Medications in 2013

<table>
<thead>
<tr>
<th>Compound</th>
<th>2005</th>
<th>2009</th>
<th>2011</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alprazolam</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Lorazepam</td>
<td>5</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Diazepam</td>
<td>9</td>
<td>10</td>
<td>9</td>
<td>11</td>
</tr>
</tbody>
</table>
Problems with Long Term Use

- Risk of CNS depression, esp with other CNS depressants
- Risk of falls and fractures
- Worsening of depression
- Cognitive and psychomotor impairment
- Diminishing effectiveness
- Physiologic dependence/addiction
Abrupt Cessation

- Rebound anxiety and panic
- Symptoms similar to alcohol withdrawal
- Delirium (similar to DTs)
- Seizures
- Self-harm, violence, psychosis, catatonia
- Can be life-threatening
Strategies to Manage Withdrawal

- Gradual dose reduction (GDR)
- Switch to a long-acting BZD with GDR
- Switch to a barbiturate and taper
- Switch to an anticonvulsant and taper
- Use of adjuncts
Managing BZD withdrawal can be an arduous and protracted process.
Can challenge the patient and the clinician.
Can be among the most difficult clinical problems one may have to deal with.
Prevention is much better than cure- handle BZDs with great caution.
Monitoring

- Frequent, short visits
- Limited duration (weeks, max)
- Tight control over prescriptions
- Drug tests
- Communication with other providers and family
- Treatment agreement
Alternatives to BZD

- Antidepressants: SSRIs; SNRIs; Tricyclics; MAOIs
- Buspirone
- Beta blockers
- Alpha 1 antagonist- prazosin
- Antipsychotics
- Anticonvulsants
Prevention

- Primary care has an important role in preventing addiction.
  - Becoming more familiar with opioid pharmacology
  - Using prescribing best practices
  - Using PDMP
  - Using CDC Guidelines for opioid use in chronic pain
  - Using FDA’s REMS
  - Identifying and assisting patients with a substance use disorder by treating or referring them to treatment
“The history of medicine is, in part, the history of physicians stretching the scope of their practice to answer the pressing needs of their times. In the face of OUD, a treatable illness with a striking capacity to rapidly and definitively alter the lives of our patients, their families, and the communities we serve, we have been late and ineffective in our response.....rates of active physician engagement in addiction treatment remain embarrassingly low.”

Resources

• PCSS-MAT: https://pcssmat.org/
  – (Free buprenorphine waiver training, webinars, online modules, clinical tools, mentoring program, etc.)

• American Society of Addiction Medicine: https://www.asam.org/

• SAMHSA-Center for Substance Abuse Treatment: https://www.samhsa.gov/about-us/who-we-are/offices-centers/csat
  – (Free publications, downloads, Treatment Locator, buprenorphine directory, waiver application, statistics, etc.)

• National Institute on Drug Abuse: https://www.drugabuse.gov/

• National Institute on Alcohol Abuse and Alcoholism: https://www.niaaa.nih.gov/
QUESTIONS?